Oral modifications and clinical presentation due to Covid-19 in oncological patients
DOI:
https://doi.org/10.33448/rsd-v11i15.37473Keywords:
Covid-19; Oral manifestations; Neoplasm.Abstract
Covid-19, originated in December 2019, spread rapidly through China, becoming a public emergency. Patients diagnosed with cancer are considered a highly vulnerable group due to their immunosuppressive condition caused by oncological treatment, therefore, this research aims to describe the clinical presentations and oral alterations in cancer patients diagnosed with Covid-19. It is a cross-sectional study with 20 oncology patients hospitalized with Covid-19. Oncological data, presence of comorbidities and symptoms related to Covid-19 were collected, and a clinical examination of the oral cavity was performed throughout the hospitalization, in order to identify oral changes. Results: The mean age of the patients was 53 years and the majority were female. Solid tumors represented 90%, the uterus being the most frequent region. Most patients were not under cancer treatment at the time of contamination (50%). Systemic arterial hypertension was the most frequent comorbidity (30%), followed by Diabetes Mellitus (25%). No patient was admitted to the ICU or required mechanical ventilation, the average length of stay was 13 days and all were hospital discharged. Cough and hypogeusia were among the most frequent symptoms. Hyposalivation and fungal infection were the most frequently observed oral alterations. Conclusion: The oral changes presented in oncological patients are in line with the findings of the literature, while the clinical presentation was contrary to the evidence that points to the oncological disease as a factor suggestive of a worse clinical condition in the face of Covid-19.
References
Brandão, T. B., et al. (2021). Oral lesions in patients with SARS-CoV-2 infection: could the oral cavity be a target organ?. Oral Surg Oral Med Oral Pathol Oral Radiol, 131 (2), 45-51. https://doi.org/10.1016/j.oooo.2020.07.014.
Dai, M., Liu, D., Liu, M., et al. (2020). Patients with Cancer Appear More Vulnerable to SARSCoV-2: A Multicenter Study during the COVID-19 Outbreak. Cancer Discov, 10 (6), 783-791. https://doi.org/10.1158/2159-8290.CD-20-0422.
García-Suárez, J., et al. (2020). Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study. J Hematol Oncol, 13 (1), 133. https://doi.org/10.1186/s13045-020-00970-7.
Guan, W. J., et al. (2020). Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J, 55 (5), 2000547. https://doi.org/10.1183/13993003.00547-2020.
Gudi, S. K., Tiwari, K. K. (2020). Preparedness and Lessons Learned from the Novel Coronavirus Disease. The IJOEM; 11 (2), 108:112. https://doi.org/10.34172/ijoem.2020.1977.
Kamboj, M., Sepkowitz, K. A. (2009). Nosocomial infections in patients with cancer. Lancet Oncol, 10, 589–97. https://doi.org/10.1016/S1470-2045(09)70069-5
Lee, L. Y., et al. (2020). COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet, 395 (10241), 1919–1926. https://doi.org/10.1016/S0140-6736(20)31173-9
Li, J. Y., et al. (2014). Selective depletion of regulatory T cell subsets by docetaxel treatment in patients with non small cell lung cancer. J Immunol Res, 2014, 286170. https://doi.org/10.1155/2014/286170
Longbottom, E. R., Torrance, H. D., Owen, H. C., et al. (2016). Features of postoperative immune suppression are reversible with interferon gamma and independent of interleukin-6 pathways. Ann Surg, 264, 370–77. https://doi.org/10.1097/SLA.0000000000001484
Marra, M. A., et al. (2003). The Genoma sequence of the SARS-associated coronavirus. Science. 300 (5624), 1399-404. https://doi.org/10.1126/science.1085953.
Miranda, R. R., et al. (2020). Head and neck cancer therapy-related oral manifestation management in the COVID-19 pandemic: a critical review. Brazilian Oral Research, 34, 1-10. http://dx.doi.org/10.1590/1807-3107bor-2020.vol34.0120.
Mole, B. (2013). Deadly pig virus slips through US borders. Nature, 499 (7459), 388– 388. https://doi.org/10.1038/499388ª.
OMS. Middle East Respiratory Syndrome Coronavirus (MERS-CoV). 2019. Available ate: https://www.who.int/emergencies/mers-cov/en/. Accessed April 17, 2020.
Pathania, A. S., et al. (2021). COVID-19 and Cancer Comorbidity: Therapeutic Opportunities and Challenges. Theranostics, 11 (2), 731-753. https://doi.org/10.7150/thno.51471.
Saini, K. S., et al. (2020). Effect of the COVID-19 pandemic on cancer treatment and research. Lancet Haematol, 7 (6), e432-5. https://doi.org/10.1016/S2352-3026(20)30123-X
Sica, A., Massarotti, M. (2017). Myeloid suppressor cells in cancer and autoimmunity. J Autoimmun, 85, 117–25. https://doi.org/10.1016/j.jaut.2017.07.010
Wu, Z., McGoogan, J. M. (2020). Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. https://doi.org/10.1001/jama.2020.2648.
Xu, X., et al. (2020). Características clínicas e de imagem de pacientes com o novo coronavírus SARS-CoV-2 de 2019. Eur J Nucl Med Mol Imaging, 47 (5), 1275 - 1280. https://doi.org/10.1007/s00259-020-04735-9.
Yang, K., et al. (2020). Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. Lancet Oncol, 21 (7), 904-913. doi:10.1016/S1470- 2045(20)30310-7.
Zaki, A.M., Van Boheemen, S., Bestebroer, T.M., Osterhaus, A.D., Fouchier, R.A. (2012). Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med., 367, 1814–20. https://doi.org/10.1056/NEJMoa1211721.
Zhang, L., et al. (2020). Características clínicas de pacientes com câncer infectados com COVID-19: um estudo de caso retrospectivo em três hospitais em Wuhan, China. Ana Oncol, 31 (7), 894-901. https://doi.org/10.1016/j.annonc.2020.03.296.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Marcos Antonio Pachêco Silva Filho; Estthelamares Lúcio da Silva Mello; Nayara Gabriela Silva Pena; Raylane Farias de Albuquerque; Lucas Nascimento Ribeiro; Maria Fernanda Limeira Feitosa; Virginia Andrade de Souza; Camila Maria da Silva; Gustavo Pina Godoy; Igor Henrique Morais Silva
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
